RetaMaps

Henry Kaw, M.D. Family Medicine

Henry Kaw, M.D. Family Medicine | PPO, CIGNA, HUMANA, MEDICARE | GLP 1 GIP Wegovy, Zepbound Ozempic Mounjaro | Urgent Care · 321 North Pomona Avenue · Fullerton, CA 92832

4.8· 464 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

Care described on the practice's website

  • GLP-1 medications named on site
  • Medically supervised weight loss

About this practice

Henry Kaw, M.D. Family Medicine | PPO, CIGNA, HUMANA, MEDICARE | GLP 1 GIP Wegovy, Zepbound Ozempic Mounjaro | Urgent Care is a medical weight-loss clinic in Fullerton, CA. Official pages describe medically supervised weight-loss care; GLP-1 medications named on the site (semaglutide, tirzepatide, liraglutide); IV wellness services; aesthetic or med-spa treatments. Care is presented as telehealth and in-person visits. It presents itself as serving adults seeking medical help with weight and metabolic health.

Services & access

Advertises semaglutide todayYes
Advertises tirzepatide todayYes
Telehealth visitsYes
Cash pay accepted—
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 4.8
Google rating · 464 reviews
15
reviews in the past year (avg ★ 3.7)
2
reviews mention GLP-1 medications
4
reviews mention weight loss

Counts computed by RetaMaps from public Google reviews; most recent review 2026-07-24. Read the reviews themselves on the practice's Google listing.

Clinicians

  • Henry Kaw, M.D. Family Medicine
  • Ppo, Cigna, Humana, Medicare
  • GLP 1 GIP Wegovy, Zepbound Ozempic Mounjaro
  • Urgent Care

Nearby providers in Fullerton

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs